Dickkopf-1 (DKK1), broadly expressed in myeloma cells but highly restricted in normal tissues, together with its functional roles as an osteoblast formation inhibitor, may be an ideal target for immunotherapy in myeloma. Our previous studies have shown that DKK1 (peptide)-specific cytotoxic T lymphocytes can effectively lyse primary myeloma cells in vitro. The goal of this study was to examine whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can control myeloma growth or even eradicate established myeloma in vivo. We used DKK1-DNA vaccine in the murine MOPC-21 myeloma model, and the results clearly showed that active vaccination using the DKK1 vaccine not only was able to protect mice from developing myeloma, but it was also therapeutic against established myeloma. Furthermore, the addition of CpG as an adjuvant, or injection of B7H1-blocking or OX40-agonist antibodies, further enhanced the therapeutic effects of the vaccine. Mechanistic studies revealed that DKK1 vaccine elicited a strong DKK1-and tumor-specific CD4
ABSTRACT
Dickkopf-1 (DKK1), broadly expressed in myeloma cells but highly restricted in normal tissues, together with its functional roles as an osteoblast formation inhibitor, may be an ideal target for immunotherapy in myeloma. Our previous studies have shown that DKK1 (peptide)-specific cytotoxic T lymphocytes can effectively lyse primary myeloma cells in vitro. The goal of this study was to examine whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can control myeloma growth or even eradicate established myeloma in vivo. We used DKK1-DNA vaccine in the murine MOPC-21 myeloma model, and the results clearly showed that active vaccination using the DKK1 vaccine not only was able to protect mice from developing myeloma, but it was also therapeutic against established myeloma. Furthermore, the addition of CpG as an adjuvant, or injection of B7H1-blocking or OX40-agonist antibodies, further enhanced the therapeutic effects of the vaccine. Mechanistic studies revealed that DKK1 vaccine elicited a strong DKK1-and tumor-specific CD4
+ and CD8 + immune responses, and treatment with B7H1 or OX40 antibodies significantly reduced the numbers of IL-10-expressing and Foxp3 + regulatory T cells in vaccinated mice. Thus, our studies provide strong rationale for targeting DKK1 for immunotherapy of myeloma patients.
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From
INTRODUCTION
Multiple myeloma (MM) is a plasma-cell malignancy that remains incurable in the vast majority of patients. After treatment with high-dose chemotherapy and autologous stemcell support, complete remission rates of 50% are achieved. However, most patients relapse 1 . Additional measures are required after transplantation to eliminate minimal residual disease. Immunotherapy is an appealing option, for this purpose, because chemotherapy and immunotherapy kill tumor cells by different modes of action that are non-cross-resistant. Therefore, these two treatment modalities should work synergistically.
Unlike other malignancies, few tumor-associated antigens have been identified in MM.
Thus far, the only myeloma antigen tested in clinical trials has been the monoclonal immunoglobulin (Ig) secreted by myeloma cells (idiotype). Immunotherapy, using idiotype-based vaccines, has been explored in myeloma patients by us and others, and the results have been disappointing [2] [3] [4] [5] , in part because of the weak immunogenicity of idiotype proteins 6, 7 . Therefore, the identification and use of novel and more potent tumorassociated antigens, especially those shared among patients, is urgently needed to improve the efficacy of immunotherapy for this disease.
Recent studies have shown that Dickkopf-1 (DKK1), a secreted protein and Wnt signaling pathway inhibitor, is highly expressed by the tumor cells of almost all myeloma patients 8 , and absent from normal tissues and organs, except placenta and prostate [9] [10] [11] .
Furthermore, myeloma-derived DKK1 may be responsible, at least in part, for suppressed osteoblast formation and bone destruction associated with MM 8 ; inhibiting DKK1 activity increased osteoblast number and bone formation, reduced osteoclast activity, and inhibited myeloma growth in a myeloma animal model 12 . Our previous results clearly show that DKK1 is expressed by primary tumor cells from all patients with MM, and DKK1 (peptide)-specific cytotoxic T lymphocytes (CTLs) can effectively lyse primary myeloma cells in vitro 13 . Hence, we hypothesize that the broad expression in myeloma but highly restricted expression in normal tissues, together with its functional roles as an osteoblast formation inhibitor and a potential myeloma growth enhancer, make DKK1 an ideal and universal target for immunotherapy in MM. The goal of our studies was to
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From explore whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can control myeloma growth or even eradicate established myeloma in vivo. In this study, we chose to use DNA vaccine because it was easy to prepare, less expensive, and had been widely used in a variety of preclinical studies [14] [15] [16] . Our results demonstrated that the DNA (murine DKK1/defensin-2 fusion) vaccine protected mice from developing myeloma and treated established myeloma in the murine MOPC-21 myeloma model 17 , in which murine DKK1 was highly expressed by the myeloma cells. We also elucidated the immunological mechanism of DKK1-DNA vaccine-mediated anti-myeloma responses.
MATERIALS AND METHODS

Myeloma cell lines and mice
Murine myeloma cell line MOPC-21 (ATCC) was maintained in Iscove modified 
Construction of plasmid for DKK1-DNA vaccine
The vector pCMVE-Chemokine-sFv for DNA vaccine was described previously 18 . To construct a plasmid encoding murine DKK1/defensin2 fusion transcript (Supplemental For personal use only. on October 31, 2017. by guest www.bloodjournal.org From cDNA insert was used as control. After amplification, plasmids were purified using Maxi-Prep Kit (Qiagen).
Identifying and synthesizing murine DKK1 peptides and H-2K d -peptide tetramers
We identified three murine DKK1 peptides using peptide binding database described previously 13 . Briefly, the sequence of murine DKK1 was reviewed for peptides that could The efficacy of the treatment, evaluated by flow cytometry by using T, B and NK cell markers, was shown to be greater than 90%.
Generation of dendritic cells (DCs)
DCs were generated from murine bone marrow stem cells as described previously 21 .
Briefly, bone marrow cells were cultured, at a density of 2 × 10 5 cells/mL in 6-well plates, in RPMI-1640 complete medium supplemented with 20 ng/mL granulocyte-monocyte colony-stimulating factor (GM-CSF; R&D Systems, Minneapolis, MN). At day 8, TNF-α (10 ng/ml) and IL-1β (10 ng/ml) (R&D Systems) were added to the immature DCs. After 48 hours of culture, mature DCs were pulsed with DKK1 peptides at a concentration of 100 μg per 10 6 DCs for 4 hours. DKK1 peptide-pulsed mature DCs were collected and used in the study.
Analysis of tumor-specific immunity
Enzyme-linked immunoabsorbent assay (ELISA) and intracellular cytokine staining were used to measure the amounts of secreted cytokines and cell expression of the cytokines.
In the ELISA for IFN-γ and IL-4, splenocytes were activated overnight (18-20 hours) with syngeneic DCs pulsed with murine DKK1 peptides and supernatants were collected and used. All ELISA assays were performed following the product instruction (R&D Systems). Intracellular cytokine staining was performed using the Cytofix/Cytoperm kit (BD Pharmingen). Samples were analyzed using a flow cytometer (FACSCalibur; Becton Dickinson 
CD8
+ T cells. Staining for cell surface molecules was performed as previously described 22 .
Antigen-specific T-cell proliferation was determined by CFSE dilution assay. Briefly, splenocytes, or cultured T cells, were labeled with 5 μM CFSE for 10 minutes at 37 o C.
After washing, labeled cells were seeded into 96-well, U-bottom plates and incubated with various stimulatory cells for 7 days. Flow cytometry analysis was used to detect dilution of CFSE, which represents T-cell proliferation 17 .
Standard 4-hour 51
Cr-release assay was performed as previously described 23 . Target effector-to-target cell ratios. After a 4-hour culture, 50% of the supernatants were collected, and radioactivity was measured. Percent specific lysis was calculated using the following formula: percent specific lysis = (experimental counts -spontaneous counts) / (maximal counts -spontaneous counts).
Statistical analysis
The Student t test was used to compare data from various experimental groups. A P value less than 0.05 was considered statistically significant. Mean and standard deviation are shown unless indicated otherwise.
RESULTS
DKK1-DNA vaccines protect mice from tumor challenge and rechallenge
In prophylactic studies, 10 Balb/c mice per group were immunized with the DNA (murine DKK1/defensin-2 fusion) vaccine before tumor challenge. As shown in Figure   1A , all mice receiving PBS injection or vector vaccine developed tumors. However, 3/10 of mice receiving DKK1-DNA vaccine survived without tumor burden by the end of the experiment period (day 90). DNA vaccine plus adjuvant CpG generated superior protection against tumor challenge and 6/10 of mice survived without tumor burdens.
Mice receiving DKK1-DNA vaccine or DKK1-DNA vaccine plus CpG had 30% or 60% 
DKK1-DNA vaccines exhibit therapeutic effect on mice with established myeloma
We evaluated the therapeutic efficacy of DKK1-DNA vaccine in mice with established myeloma. In these experiments, DKK1-DNA vaccine plus CpG was used as a standard vaccine. Our previous work has shown that targeting the suppressive tumor microenvironment and breaking immune suppression on effector T cells can enhance the immunogenicity of the vaccines and cure mice with large tumor burden 17 . Therefore, we used anti-B7H1 (M5H1) mAb 24 to block negative T-cell signaling and anti-OX40 (OX86) mAb [25] [26] [27] to overcome CD4 + T cell tolerance in mice receiving DKK1-DNA vaccination.
As shown in Figure 2A 
DKK1-DNA vaccines induce CD4 + and CD8 + T-cell responses against tumor cells
To demonstrate DKK1-DNA vaccine-induced anti-myeloma immunity, we assessed whether CD4 + and CD8 + T cells were activated after DNA vaccine and tumor inoculation.
Mice were vaccinated thrice followed by tumor injection, and two weeks after tumor injection, mice were sacrificed, and splenocytes were isolated and cultured ex vivo with irradiated myeloma cells for 5 days. Intracellular cytokine staining showed that DKK1 DNA-vaccinated mice had more tumor-specific IFN-γ and IL-4 expressing CD4 + (P < 0.05 for both IFN-γ and IL-4; Figure 3A ) and CD8 + (P < 0.01 for IFN-γ and P < 0. were reduced in the spleens and tumors of vaccinated mice compared with control mice (P < 0.05 in spleens and P < 0.01 in tumors in DNA vaccine alone, and P < 0.01 in both in DNA vaccine plus CpG; Figure 3C ), and more CD3 + CD8 + T cells were detected in the tumors but not spleens of vaccinated mice (P < 0.05), especially in mice vaccinated together with CpG (P < 0.01; Figure 3D ). Overall, these data showed that strong tumorspecific CD4 + and CD8 + T-cell responses were elicited following DKK1-DNA vaccination, and tumor-specific CD8 + CTLs might play an important role in vaccineinduced anti-myeloma immunity.
Next, we examined the role of CD4 + and CD8 + T cells, and NK cells in DKK1-DNA vaccine-induced anti-myeloma immunity in vivo by using antibody depletion assay. As shown in Figure 4A , mice receiving DKK1 vaccine plus CpG had repressed tumor growth, which was abrogated in mice depleted of CD4 + (P < 0.05, compared with control) or CD8 + (P < 0.01) T cells but not NK cells. Importantly, CD8 + T-cell depletion led to a total loss of the vaccine-induced protection. Figure 4B shows the survival data of the mice. Thus, this data confirms the importance of vaccine-induced CD4 + and, especially, CD8 + T-cell responses in anti-tumor immunity in the mouse model.
DKK1-DNA vaccine induces anti-DKK1 antibody production
In addition to cellular immunity, we also observed anti-DKK1 antibody production after the DNA vaccine. Mouse serum was collected every week and tested for anti-DKK1
antibodies by ELISA. Figure 4C shows that anti-DKK1 antibodies were induced by DKK1-DNA vaccination.
To evaluate the role of the antibodies or B cells in DKK1-DNA vaccine-induced antitumor responses in vivo, we depleted B cells by using anti-CD20 mAb. Our preliminary studies showed that more than 90% of B cells were depleted by the treatment and anti-DKK1 antibodies were undetectable in mice depleted of B cells (data not shown).
As shown in Figure 4D , there were no significant differences in myeloma development in the three groups. In all groups, 3 out of 5 mice were protected from developing myeloma (data not shown). These results demonstrate that anti-DKK1 antibodies or B cells may not play a role in controlling the growth of myeloma cells in vivo.
DKK1-DNA vaccine induces DKK1-specific CTL response
Our data showed that DKK1-DNA vaccine induced CD8 + T-cell activation and depletion of CD8 + T cells significantly affected vaccine-induced anti-tumor activity. To examine CTL response, we first detected cytotoxicity of splenocytes in mice after DNA vaccine.
As shown in Figure 5A , splenocytes from DKK1 DNA-vaccinated mice efficiently killed the myeloma cells in vitro. No tumor-specific CTL activity was detected in control mice.
To confirm the specificity of the T cells from immunized mice, three DKK1 peptides, potentially binding to H-2K d molecules, were used (Table 1) . By using DKK1 peptidetetramer staining and CFSE dilution assay, DKK1-specific CD8 + T cells were detected in mice receiving DKK1-DNA vaccination. As shown by a representative staining using three different DKK1 peptide-tetramers depicted in Figure 5B , DKK1-DNA vaccination, especially vaccination plus CpG, stimulated DKK1 peptide-specific CD8 + T-cell response in the mice.
Second, we used CFSE dilution assay to examine DKK1 peptide-specific T cells from mice receiving DKK1-DNA vaccination. As shown in Figure 5C , DKK1-specific CD8 + T cells proliferated in response to syngeneic DCs pulsed, but not unpulsed, with DKK1 peptides P11, P15 and P210 (P < 0.01, compared with unpulsed DC) but not with a control influenza-A peptide HA533.
Third, we examined cytokines secreted by T cells from DKK1-DNA-vaccinated mice.
Figures 5D and 5E show that IFN-γ and IL-4 secretion was significantly increased in splenic T cells restimulated with DKK1 peptide-pulsed DCs, but not with unpulsed DCs.
Taken together, these data demonstrate that DKK1-specific T cells and CD8 + CTLs were generated after DKK1-DNA vaccination.
B7H1 or OX40 antibodies downregulate regulator T cells in vivo
We showed previously in this study that anti-B7H1 or OX40 mAbs enhanced the therapeutic efficacy of DKK1-DNA vaccine, and studies were performed to elucidate the underlying immunological mechanism. As shown in Figure 6 , the percentages of IL-10-secreting or Foxp3 + Tregs in the spleens and tumors were significantly decreased in mice vaccinated with DKK1-DNA plus CpG in combination with anti-B7H1 or anti-OX40 antibodies (P < 0.01, compared with mice receiving DKK1 DNA alone). These results indicate that the beneficial effects of anti-B7H1 or OX40 mAbs were derived from their ability to reduce the numbers of Tregs in tumor-bearing mice.
Discussion
The goal of this study was to examine whether DKK1 can be used as a tumor vaccine to elicit DKK1-specific immunity that can control myeloma growth or even eradicate Active immunotherapy, using tumor-associated antigens (vaccination), is considered as one of potentially promising cancer immunotherapy approaches 31 . Among different forms of tumor vaccines, DNA vaccine strategy allows broad usage [14] [15] [16] . Studies have shown that anti-tumor immunity can be triggered by targeting antigen delivery to antigenpresenting cells by chemokine receptor-mediated binding, uptake, and processing of tumor antigen for more efficient presentation to T cells. These fusion vaccines have been shown to elicit much more potent anti-tumor effects, compared to the unfused counterpart, in several mouse tumor models 18, 32 . The chemokine motif in the fusion has been shown to be essential for breaking immune tolerance of tumor antigen since vaccination of plasmid DNA that encodes the fusion elicited potent antigen-specific immune responses, while their non-fused counterparts did not 32 . Moreover, the chemokine needs to be physically linked with the antigen as the anti-tumor immunity was not detected in mice co-injected with the non-fusion antigen and the chemokine adjuvant 18, 32 . Among the panel of 18, 32 . Though initially tested for its ability to interact with CC chemokine receptor 6 18 , defensin-2 has been shown to play a role in activating antigen-presenting cells via
Toll-like receptor 4 (TLR4) 32 . Thus, its dual capacity to target antigen-presenting cells and to induce DC maturation makes defensin-2 an attractive candidate for chemokine fusion vaccines 18, 32 Therefore, we designed the expression plasmid encoding DKK1
cDNA-defensin-2 fusion gene for this study. Recently, molecular homologs of B7-like ligands, B7H1 (also termed PDL1) and B7DC
(also termed PDL2), have been identified. PD-1, their receptor, is a 55-kDa type 1 . Thus, B7H1 or B7DC lead to diminished immune responses by regulating T-cell activation. Unlike the response to foreign pathogens, which elicit potent danger signals, the immune response to tumor antigens is usually less robust and the tumor environment can be immunosuppressive, leading to antigen-specific T-cell tolerance 41 .
On the other hand, signaling through OX40 in vivo leads to a series of pro-inflammatory events that can overcome CD4 + T-cell tolerance 27, 42 . Agonist antibodies and a soluble OX40L-immunoglobulin fusion protein have been injected in vivo to test their ability to enhance immune responses in tumor-bearing mice [43] [44] [45] . Ligation of OX40 in vivo in tumor-bearing mice enhanced anti-tumor immunity, leading to tumor-free survival in mouse models of melanoma, sarcoma, colon cancer, breast cancer and glioma [43] [44] [45] [46] [47] Also, a recent study has shown that OX40 signals might contribute to the deletion and There are advantages with active DKK1 vaccination. First, it can induce DKK1-specific T-cell responses including CTLs that can directly kill myeloma cells. Second, DKK1
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From vaccines can also elicit anti-DKK1 antibodies, which could inhibit myeloma-related bone disease in patients.
In conclusion, our study suggests that DKK1-DNA vaccine can be used as a universal tumor vaccine for immunotherapy of patients with MM. This is supported by our results that DKK1-DNA vaccines provided strong protection against mice from developing myeloma and was effective at treating established myeloma in the mouse model. Furthermore, by using CpG, B7H1 blocking or OX40 agonist antibodies, the therapeutic efficacy of DKK1-DNA vaccines can be greatly improved to eradicate tumors developed in the mice. Thus, this study is the first preclinical study to provide strong and direct evidence to support the application of DKK1-based immunotherapy in MM. Representative results of one out of two independent experiments performed are shown. *P < 0.05; **P < 0.01, compared with controls. For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
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